Background & Aims The cellular immunity has a profound impact on the status of hepatitis C virus (HCV) infection. However, the response of cellular immunity on the virological response in patients with antiviral treatment remains largely unclear. We aimed to clarify the response of peripheral T cells and monocytes in chronic hepatitis C patients with antiviral treatment. Methods Patients with chronic hepatitis C were treated either with interferon alpha-2b plus ribavirin (n = 37) or with pegylated interferon alpha-2a plus ribavirin (n = 33) for up to 24 weeks. Frequencies of peripheral regulatory T-cells (Tregs), programmed death-1 (PD-1) expressing CD4+ T-cells or CD8+ T-cells and toll-like receptor (TLR) 3 expressing CD14+ monocytes were evaluated by flow cytometry in patients at baseline, 12 and 24 weeks following treatment and in 20 healthy controls. Results Frequencies of Tregs, PD-1 and TLR3 expressing cells were higher in patients than those in control subjects (P<0.05). Patients with complete early virological response (cEVR) showed lower Tregs, PD-1 expressing CD4+ or CD8+ T-cells than those without cEVR at 12 weeks (P<0.05). Patients with low TLR3 expressing CD14+ monocytes at baseline had a high rate of cEVR (P<0.05). Conclusions Low peripheral TLR3 expressing CD14+ monocytes at baseline could serve as a predictor for cEVR of antiviral therapy in chronic HCV-infected patients. The cEVR rates were significantly increased in the patients with reduced circulating Tregs, PD-1 expressing CD4+ or CD8+ T-cells. Trial Registration Chinese Clinical Trial Registry ChiCTR10001090.
References
[1]
Hadigan C, Kottilil S (2011) Hepatitis C virus infection and co-infection with human immunodeficiency virus: challenges and advancements in management. JAMA 306: 294–301. doi: 10.1001/jama.2011.975
[2]
Munir S, Saleem S, Idrees M, Tariq A, Butt S, et al. (2010) Hepatitis C treatment: current and future perspectives. Virol J 7: 296. doi: 10.1186/1743-422x-7-296
[3]
Shepard CW, Finelli L, Alter MJ (2005) Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 5: 558–567. doi: 10.1016/s1473-3099(05)70216-4
[4]
Marukian S, Jones CT, Andrus L, Evans MJ, Ritola KD, et al. (2008) Cell culture-produced hepatitis C virus does not infect peripheral blood mononuclear cells. Hepatology 48: 1843–1850. doi: 10.1002/hep.22550
[5]
Shiina M, Rehermann B (2008) Cell culture-produced hepatitis C virus impairs plasma cytoid dendritic cell function. Hepatology 47: 385–395. doi: 10.1002/hep.21996
[6]
Zheng Y, Rudensky AY (2007) Foxp3 in control of the regulatory T cell lineage. Nat Immunol 8: 457–462. doi: 10.1038/ni1455
[7]
Speletas M, Argentou N, Germanidis G, Vasiliadis T, Mantzoukis K, et al. (2011) Foxp3 expression in liver correlates with the degree but not the cause of inflammation. Mediators Inflamm 827565: 1–9. doi: 10.1155/2011/827565
[8]
Tseng KC, Ho YC, Hsieh YH, Lai NS, Wen ZH, et al. (2012) Elevated frequency and function of regulatory T cells in patients with active chronic hepatitis C. J Gastroenterol. 47: 823–833. doi: 10.1007/s00535-012-0544-9
[9]
Sarikonda G, von Herrath MG (2011) Immunosuppressive mechanisms during viral infectious diseases. Methods Mol Biol 677: 431–447. doi: 10.1007/978-1-60761-869-0_27
[10]
Nakamoto N, Cho H, Shaked A, Olthoff K, Valiga ME, et al. (2009) Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade. PLoS Pathog 5: e1000313. doi: 10.1371/journal.ppat.1000313
[11]
Nakamoto N, Kaplan DE, Coleclough J, Li Y, Valiga ME, et al. (2008) Functional restoration of HCV-specific CD8 T cells by PD-1 blockade is defined by PD-1 expression and compartmentalization. Gastroenterology 134: 1927–1937. doi: 10.1053/j.gastro.2008.02.033
[12]
Urbani S, Amadei B, Tola D, Pedrazzi G, Sacchelli L, et al. (2008) Restoration of HCV-specific T cell functions by PD-1/PD-L1 blockade in HCV infection: effect of viremia levels and antiviral treatment. J Hepatol 48: 548–558. doi: 10.1016/j.jhep.2008.07.008
[13]
Missale G, Pilli M, Zerbini A, Penna A, Ravanetti L, et al. (2012) Lack of full CD8 functional restoration after antiviral treatment for acute and chronic hepatitis C virus infection. Gut 61: 1076–1084. doi: 10.1136/gutjnl-2011-300515
[14]
Pasare C, Medzhitov R (2003) Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 299: 1033–1036. doi: 10.1126/science.1078231
[15]
Hackl D, Loschko J, Sparwasser T, Reindl W, Krug AB (2011) Activation of dendritic cells via TLR7 reduces Foxp3 expression and suppressive function in induced Tregs. Eur J Immunol 41: 1334–1343. doi: 10.1002/eji.201041014
[16]
Thomas A, Laxton C, Rodman J, Myangar N, Horscroft N, et al. (2007) Investigating Toll-like receptor agonists for potential to treat hepatitis C virus infection. Antimicrob Agents Chemother 51: 2969–2978. doi: 10.1128/aac.00268-07
[17]
Gao YT, Chen RY, Song WQ, Chen CB, Qi ZL, et al. (2004) Prepare and clinical application of HCV genotyping oligochip. Chin J Lab Med 27: 690–693.
[18]
Ghany MG, Nelson DR, Strader DB, Thomas DL (2011) Seeff LB; American Association for Study of Liver Diseases (2011) An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 54: 1433–1444. doi: 10.1002/hep.24641
[19]
Chung HJ, Lee JW, Kim YS, Lee JI (2013) Prediction of sustained virologic response based on week 4 and week 12 response in hepatitis C virus genotype 1 patients treated with peginterferon and ribavirin: assessment in a favorable IL28B allele-prevalent area. Intervirology 56: 178–183. doi: 10.1159/000345539
[20]
Huang CF, Yang JF, Huang JF, Dai CY, Chiu CF, et al. (2010) Early identification of achieving a sustained virological response in chronic hepatitis C patients without a rapid virological response. J Gastroenterol Hepatol 25: 758–765. doi: 10.1111/j.1440-1746.2009.06148.x
[21]
Rodriguez-Torres M, Sulkowski MS, Chung RT, Hamzeh FM, Jensen DM (2010) Factors associated with rapid and early virologic response to peginterferon alfa-2a/ribavirin treatment in HCV genotype 1 patients representative of the general chronic hepatitis C population. J Viral Hepat 17: 139–147. doi: 10.1111/j.1365-2893.2009.01157.x
[22]
Hashad DI, Salem PE, Abdallah DM (2011) Toll like receptor 3 expression as a novel predictor of response to treatment in chronic hepatitis C virus patients. Scand J Clin Lab Invest 71: 641–646. doi: 10.3109/00365513.2011.624196
[23]
Yuki N, Matsumoto S, Kato M, Yamaguchi T (2010) Hepatic Toll-Like Receptor 3 expression in chronic hepatitis C genotype 1 correlates with treatment response to peginterferon plus ribavirin. J Viral Hepat 17: 130–138. doi: 10.1111/j.1365-2893.2009.01155.x
[24]
Liao XW, Ling Y, Li XH, Han Y, Zhang SY, et al. (2011) Association of genetic variation in IL28B with hepatitis C treatment-induced viral clearance in the Chinese Han population. Antivir Ther 16: 141–147. doi: 10.3851/imp1703
[25]
Kamal SM, Fehr J, Roesler B, Peters T, Rasenack JW (2002) Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C. Gastroenterology. 123: 1070–1083. doi: 10.1053/gast.2002.36045
[26]
Fitzmaurice K, Klenerman P (2008) Cellular immunity and acute hepatitis C infection. Curr Pharm Des 14: 1666–1677. doi: 10.2174/138161208784746806
[27]
Bowen DG, Walker CM (2005) Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 436: 946–952. doi: 10.1038/nature04079
[28]
Frebel H, Richter K, Oxenius A (2010) How chronic viral infections impact on antigen-specific T-cell responses. Eur J Immunol 40: 654–663. doi: 10.1002/eji.200940102
[29]
Yao S, Wang S, Zhu Y, Luo L, Zhu G, et al. (2009) PD-1 on dendritic cells impedes innate immunity against bacterial infection. Blood 113: 5811–5818. doi: 10.1182/blood-2009-02-203141
[30]
Golden-Mason L, Palmer B, Klarquist J, Mengshol JA, Castelblanco N, et al. (2007) Upregulation of PD-1 expression on circulating and intrahepatic hepatitis C virus-specific CD8+ T cells associated with reversible immune dysfunction. J Virol 81: 9249–9258. doi: 10.1128/jvi.00409-07
[31]
Rutebemberwa A, Ray SC, Astemborski J, Levine J, Liu L, et al. (2008) High-programmed death-1 levels on hepatitis C virus-specific T cells during acute infection are associated with viral persistence and require preservation of cognate antigen during chronic infection. J Immunol 181: 8215–8225. doi: 10.4049/jimmunol.181.12.8215
[32]
Shen T, Zheng J, Liang H, Xu C, Chen X, et al. (2011) Characteristics and PD-1 expression of peripheral CD4+CD127l°CD25hiFoxP3+ Treg cells in chronic HCV infected-patients. Virol J 8: 279. doi: 10.1186/1743-422x-8-279
[33]
Feld JJ, Hoofnagle JH (2005) Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature. 436: 967–972. doi: 10.1038/nature04082
[34]
Bengsch B, Seigel B, Ruhl M, Timm J, Kuntz M, et al. (2010) Coexpression of PD-1, 2B4, CD160 and KLRG1 on exhausted HCV-specific CD8+ T cells is linked to antigen recognition and T cell differentiation. PLoS Pathog 6: e1000947. doi: 10.1371/journal.ppat.1000947
[35]
Seigel B, Bengsch B, Lohmann V, Bartenschlager R, Blum HE, et al. (2013) Factors that determine the antiviral efficacy of HCV-specific CD8(+) T cells ex vivo. Gastroenterology 144: 426–436. doi: 10.1053/j.gastro.2012.10.047
[36]
Raziorrouh B, Ulsenheimer A, Schraut W, Heeg M, Kurktschiev P, et al. (2011) Inhibitory molecules that regulate expansion and restoration of HCV-specific CD4+ T cells in patients with chronic infection. Gastroenterology 141: 1422–1431. doi: 10.1053/j.gastro.2011.07.004
[37]
Golden-Mason L, Klarquist J, Wahed AS, Rosen HR (2008) Cutting edge: programmed death-1 expression is increased on immunocytes in chronic hepatitis C virus and predicts failure of response to antiviral therapy: race-dependent differences. J Immunol 180: 3637–3641. doi: 10.4049/jimmunol.180.6.3637
[38]
Langhans B, Nischalke HD, Arndt S, Braunschweiger I, Nattermann J, et al. (2012) Ribavirin exerts differential effects on functions of Cd4+ Th1, Th2, and regulatory T cell clones in hepatitis C. PLoS One. 7: e42094. doi: 10.1371/journal.pone.0042094
[39]
Gay NJ, Gangloff M (2007) Structure and function of Toll receptors and their ligands. Annu Rev Biochem 76: 141–165. doi: 10.1146/annurev.biochem.76.060305.151318
[40]
Schroder M, Bowie AG (2005) TLR3 in antiviral immunity: key player or bystander? Trends Immunol 26: 462–468. doi: 10.1016/j.it.2005.07.002
[41]
Villacres MC, Literat O, DeGiacomo M, Du W, Frederick T, et al. (2008) Defective response to Toll-like receptor 3 and 4 ligands by activated monocytes in chronic hepatitis C virus infection. J Viral Hepat 15: 137–144. doi: 10.1111/j.1365-2893.2007.00904.x
[42]
Sarasin-Filipowicz M, Oakeley EJ, Duong FH, Christen V, Terracciano L, et al. (2008) Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci USA. 105: 7034–7039. doi: 10.1073/pnas.0707882105
